EnWave sees its highest-ever quarterly returns for cannabis

A successful 2019 was reported for the Canadian food, medical and cannabis company EnWave; a year in which many important milestones were reached. This is also reflected in the strong figures for the last quarter and the full year of 2019. The Canadian company reported record sales of around $32.50 million (CA$42.84 million) in 2019 compared to around $17.31 million (CA$22.82 million) in 2018.

EnWave signed a total of 14 new commercial license agreements in 2019. Seven of them in cannabis and hemp, six in food and one in medicine.

Additonally, EnWave was also selected as a “Venture 50” company in the “Clean Technology and Life Sciences” category.

The Hemp.im application organizes what’s happening in the cannabis world to help you learn more about the stories that matter to you.

Stay informed with the latest hemp news and get the important information in one application.

Record quarterly returns for cannabis in Canada

Canadian companies reported record sales of around $32.50 million (CA$43 million) in 2019 compared to around $17.31 million ($CA23 million) in 2018. Quarterly returns for cannabis increased by almost $15.18 million (CA$21 million) or 88%.

The strong sales growth is due to the expanded distribution of “Moon Cheese” over the course of the year and the highest number of license agreements to date for “REV” machine contracts.

EnWave’s gross profit increased from around $6.75 million (CA$8.8 million) in 2018 to around $10.32 million (CA$13.55 million) in 2019. This corresponds to an increase of around $3.56 million (CA$4.7 million) or 53%. The gross margin was 32% in 2019 compared to 39% in 2018.

High investments fueling high quarterly returns for cannabis

A strategic investment by Aurora Cannabis Inc. in EnWave, with gross proceeds totaling more than $7.58 million (CA$10 million), was also completed to finance future growth and economically adapt the two companies’ international license agreements.

The balance sheet was strengthened with cash equivalents of around $14.15 million (CA$18.66 million) as of September 30, 2019. The debt-free company is thus solidly financed, which is a good starting position for possible financing of future growth.

Sales increase in 2019

The individual figures for the last quarter of 2019 are as follows. EnWave increased its sales in Q4-2019 to around $16.2 (CA$21.33 million) compared to around $5.56 million (CA$7.35 million) in the same accounting period of the previous year. As a result, this represents a solid increase of more than $6.69 million (CA$8.83 million) or 120%.

The increase in quarterly returns for cannabis is due to a strong dividend increase to Costco in the fourth quarter of 2019 for the Most Valuable Member (MVM) coupon program and the growth in the number of “REV” machines sold. With this result, the company achieved the highest quarterly sales in its history.

__

(Featured image by William Iven via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Vestors Capital, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.